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Abstract. Primary mitochondrial diseas-
es (MD) are complex, heterogeneous inherit-
ed diseases caused by mutations in either the 
mitochondrial or nuclear DNA. Glomerular 
diseases in MD have been reported with tRNA 
mutation m.3243A>G causing a syndrome 
of mitochondrial encephalomyopathy, lactic 
acidosis and stroke-like episodes (MELAS). 
We describe here a case of focal segmental 
glomerulosclerosis (FSGS) associated with a 
new tRNA mutation site. A 34-year-old man 
with a history of living related kidney trans-
plantation, diabetes, hearing loss, and devel-
opmental delay presented to the outpatient 
clinic with complaints of new behavioral 
difficulties, worsening symptoms, and brain 
involvement on imaging. Physical examina-
tion was remarkable for difficulty hearing, a 
pattern of dysarthric speech, and cerebellar 
gait. Laboratory investigations including lac-
tate levels were unremarkable. Based on this 
set of clinical circumstances, concern for an 
underlying genetic abnormality was raised. 
Multiple metabolic tests were unremarkable. 
Whole exome sequencing revealed a mito-
chondrial  MT-TW tRNA change at position 
m.5538G>A. Genotype-phenotype correla-
tions are consistent with this tRNA muta-
tion as a cause of his symptoms. To the best 
of our knowledge, this is the first case de-
scribing FSGS-associated MD caused by an 
m.5538 G>A mutation. Consideration of an 
underlying MD should be made in patients 
presenting with deafness, neurologic chang-
es, diabetes, and renal failure.
Introduction
Friedrich Nietzsche (1844 – 1900) was 
perhaps one of the most influential German 
philosophers in history [1]. His medical bi-
ography has intrigued many for decades, 
exemplifying a constellation of seemingly 
unrelated symptoms involving multiple or-
gan systems, and has been a subject of con-
troversy. Today, his symptoms have been 
widely thought to be secondary to a form of 
mitochondrial disease (MD) called  MELAS 
syndrome that includes mitochondrial en-
cephalopathy, lactic acidosis, and stroke-
like episodes. MELAS syndrome is associ-
ated in ~ 80% of cases with a mitochondrial 
gene mutation at position m.3243A>G [2]. 
Primary MDs are complex, heterogeneous 
inherited diseases and they can be caused 
by mutations in either the mitochondrial or 
nuclear DNA. Mitochondria are transferred 
from mothers to their progeny in the oocyte 
and therefore genetic conditions involving 
the mitochondrial DNA follow a maternal in-
heritance [3]. Phenotypic expression of MDs 
can be highly variable [3] in part reflecting 
the ubiquitous distribution of mitochondria 
potentially affecting all tissues and organs.
Over the past two decades, several pat-
terns of renal diseases have been associated 
with MDs, including glomerular disease, tu-
bulopathies, cystic disease, and tubulointer-
stitial nephritis [4]. The majority of patients 
diagnosed with MD-associated renal disease 
are in their second or third decade of life and 
over half of these patients have chronic kid-
ney disease (CKD) [3]. While renal involve-
ment in MELAS syndrome is uncommon, 
patients with m.3243A>G mutations can de-
velop renal failure and proteinuria usually in 
association with diabetes, sensorineural hear-
ing loss, and other neuromuscular deficits. It 
is estimated that ~ 1% of the diabetic popula-
tion in Europe and Japan carry this genetic 
defect [5]. Approximately 80% of patients 
with renal involvement have a hearing im-
pairment and these patients can be mislead-
ingly diagnosed with Alport’s syndrome [6]. 
The prevalent histological renal pathology 
finding in these patients with mitochondrial 
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DNA point mutations is focal segmental glo-
merulosclerosis (FSGS) [7].
Only a rare few other mitochondrial 
point mutations have been described to be 
associated with FSGS, and these are lo-
cated at m.4269A>G, m.5728A>G, and 
m.A5843A>G [8]. Patients with mitochon-
drial DNA deletions that cause Kearns-Sayre 
[9, 10] and Pearson syndromes [11] rarely 
have glomerular pathologies and most of-
ten develop renal tubular dysfunction and 
interstitial nephritis. We describe here a 
case of FSGS-associated MD caused by an 
m.5538G>A mutation, which to the best of 
our knowledge is the first of its kind. An ad-
ditional unique feature of this is the complex 
multiorgan involvement on a background of 
developmental delay, hearing loss, diabetes, 
and renal failure.
Case report
A 34-year-old man with a history of end-
stage renal disease (ESRD) who underwent 
living related kidney transplantation in 2005 
and had diabetes, hearing loss, hypertension, 
and mild developmental delay presented to 
the outpatient clinic with complaints of static 
encephalopathy (permanent or unchanging 
brain dysfunction) and worsening MRI find-
ings of progressive cortical and subcortical 
atrophy, calcification of the bilateral basal 
ganglia and cerebellar dentate nuclei, sub-
cortical white matter changes, and corpus 
callosum lesions. At age 12, he first noted bi-
lateral progressive hearing decline secondary 
to a sensorineural deficit. At age 14, he de-
veloped non-nephrotic range proteinuria and 
underwent kidney biopsy that showed FSGS. 
He subsequently developed ESRD and re-
quired hemodialysis prior to receiving a liv-
ing related kidney transplant from his father 
by age 24. Following his kidney transplanta-
tion, he developed steroid-induced diabetes. 
His kidney transplant course has otherwise 
been uncomplicated and he has had no in-
dication for an allograft biopsy. At the time 
of his clinic visit with us, his mother noted 
him to have new behavioral difficulties, spe-
cifically disorganized thought processes with 
complaints of disorderly conduct likely re-
lated to worsening brain abnormalities and 
raising concern for an underlying genetic 
abnormality. During evaluation, the patient 
also suffered a stroke of the posterior right 
lentiform nucleus and posterior limb of the 
right internal capsule.
His social history was negative for to-
bacco, alcohol, or illicit drug usage. The pa-
tient was able to finish high school and at-
tend a year in community college. He was 
the product of a normal pregnancy after a 
prior miscarriage. His family pedigree is 
illustrated in Figure 1. His medications in-
cluded mycophenolate mofetil, tacrolimus, 
gemfibrozil, esomeprazole, and vitamin D. 
He has no allergies. Physical examination 
was remarkable for a mild cerebellar gait, 
decreased hearing, otherwise all other sys-
tems were largely negative including normal 
retinal exam.
Laboratory investigations including 
lactate levels and other metabolic profiles 
were unremarkable. Whole exome sequenc-
ing revealed a mitochondrial MT-TW tRNA 
change at position m.5538G>A with 30% 
heteroplasmy (HTP) in blood as well as 
Figure 1. Family pedigree.
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several variants of unknown significance in 
genes associated to diseases that do not cor-
relate with patient’s phenotype or may only 
have a slight contribution to symptoms as 
illustrated in Figure 2. Genotype-phenotype 
correlation in this case is most consistent 
with this tRNA mutation as a cause of this 
patient’s symptoms.
Discussion
There is a paucity of data on genetic mi-
tochondrial defects and their renal manifes-
tations both in pediatric patients, and even 
more so in adults [4]. This is reflective of 
their designation as rare diseases, pheno-
typic, and genotypic heterogeneity making 
them difficult to recognize and begging the 
need for initiatives to raise awareness, and 
improve diagnostic and therapeutic strate-
gies for the care of patients afflicted with 
MDs. Organ systems and tissue types that 
are most severely affected by MDs are those 
that are reliant on aerobic metabolism for 
ATP production and oxidative phosphoryla-
tion, and this is particularly the case for the 
central nervous system and skeletal muscle. 
Renal manifestations in MDs are rarely de-
scribed in isolation and therefore the coexis-
tence of neuromuscular symptoms and renal 
manifestations should raise the suspicion of 
an underlying MD [3]. Identifying specific 
mutation sites involved in mitochondrial-
associated renal diseases can help inform our 
diagnostic approaches while yielding valu-
able insight into the genetics of these con-
ditions. The case presented here therefore 
provides critical information on a new mito-
chondrial MT-TW tRNA change at position 
m.5538G>A that is potentially associated 
with the development of FSGS.
The m.3243A>G point mutation is the 
most commonly described mutation to date in 
MDs that has been linked to renal disease. In 
our case, whole exome sequencing did not re-
veal the presence of this point mutation. Sev-
eral other gene variants were revealed in our 
patient (Figure 2), however following litera-
ture review, genetic database consultation and 
detailed phenotyping of patient, the known 
conditions associated with these variants were 
not present in our case. Variant in the PDG-
FRB gene found in the case is common in the 
general population and is associated with fa-
milial brain calcification, however this variant 
could not account for the constellation of the 
other phenotypic changes that were present in 
our patient. Additionally, none of these other 
variants have been associated with FSGS to 
the best of our knowledge.
Mitochondrial tRNA mutations have 
been involved in a host of syndromes rang-
ing from single symptom to multi-systemic 
disease. The tRNATrp mutation found in this 
patient has been linked to mitochondrial my-
opathy, Leigh syndrome, myoclonic epilep-
sy, and various encephalomyopathies [12]. 
Skeletal muscles usually reveal ragged red 
fibers, cytochrome C oxidase negative fibers, 
abnormal mitochondria on electron micros-
copy, and electron transport chain deficien-
cies on biochemical testing [13]. Due to our 
patient’s frail condition and multiple co-mor-
Figure 2.  Results of whole exome sequencing.
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bidities, a muscle biopsy was declined. Mi-
tochondrial function tests such as respiratory 
chain enzyme activities can be performed on 
fresh renal tissue, but this is mostly available 
on a research basis [4]. Tissue can also be 
obtained from other sources such as in blood 
peripheral leukocytes and skin fibroblasts for 
functional analysis however, MDs and their 
manifestations can be tissue specific and 
therefore some cases can be missed. A limi-
tation of our case presented is that we were 
unable to obtain kidney tissue for functional 
analysis. Serum lactate levels have gener-
ally been measured in cases of suspected 
MDs, however lactate levels can be normal 
such as in our patient [4]. This means that 
the diagnosis of MDs relies upon recogni-
tion of clinical manifestations and informa-
tion obtained from a detailed family history 
ultimately confirmed by molecular testing. 
Due to these factors, the incidence of renal-
associated MDs is in all likelihood underes-
timated. Known mitochondrial tRNA muta-
tions that have been associated with kidney 
disease are summarized in Table 1.
Interestingly, 2 other patients who have 
been reported carrying the m.5538G>A mu-
tation had very different symptoms compared 
to our patient which included myoclonic epi-
lepsy, cataract, pigmentary retinopathy, hy-
pothyroidism, and mild myopathy in the pro-
band (65% HTP in muscle, 5% in blood) and 
only hypothyroidism and diabetes mellitus in 
the proband’s mother (20% HTP in muscle) 
[13]. This discrepancy is not uncommon with 
mtDNA disease and may be related to muta-
tion heteroplasmy level and tissue segrega-
tion. Our patient was noted to develop diabe-
tes after beginning steroid therapy as part of 
his immunosuppressive regimen. However, 
it is likely that his mitochondrial disease pre-
disposed him to develop diabetes at such an 
early age. We also note that other anti-codon 
stem mutations in the mitochondrial transfer 
RNATrp at position m.5540G>A present with 
early onset hearing loss, abnormal brain im-
aging including basal ganglia calcification, 
and marked overall brain atrophy with white 
matter changes very much similar to our case 
[14]. None of the patients reported with the 
m.5540G>A mutation had any renal involve-
ment but they were young in age compared 
to our patient and kidney involvement may 
have been missed at the time of the initial 
evaluation. 
Due to the association of MDs with deaf-
ness and difficulties with defining clear in-
heritance patterns in some cases, patients 
with MDs can be mistakenly diagnosed with 
Alport’s syndrome [5]. On review of two 
studies that screened a total of 90 patients 
with Alport’s syndrome for the MELAS mu-
tation, 2 patients were found to be misdiag-
nosed [5, 15]. In MDs, hematuria is usually 
absent and disruption of the glomerular base-
ment-membrane characteristic of Alport’s 
syndrome on renal histopathology is also ab-
sent. Therefore, the presence or absence of 
hematuria may help to distinguish between 
MDs and Alport’s syndrome. Of note, pa-
tients with Alport’s syndrome can present 
with FSGS on kidney biopsy and therefore, 
this cannot be used as a feature to distinguish 
between the two conditions [16, 17]. Muta-
tions in the COL4A3-5 genes that encode 
α-chains of glomerular basement membrane 
Table 1. Mitochondrial DNA mutations associated with kidney disease.
Mutation Gene Renal phenotype Reference
m.G5538A mt-tRNA FSGS First described in this case report
m.G586A mt-tRNA TIN [20]
m.A608G mt-tRNA TIN [21]
m.G3242A mt-tRNA Renal failure, RTA type 4 [22]
m.A3243G mt-tRNA FSGS [2, 8]
m.A3243G mt-tRNA TIN [23, 24]
m.A4269G mt-tRNA FSGS [25]
m.A5656G Noncoding region TIN [26]
m.A5728G mt-tRNA FSGS [27]
m.A5843G mt-tRNA FSGS [28]
m.12425delA NADH dehydrogenase 5 Glomerulocystic disease, renal failure [29]
Mt-tRNA = mitochondrial transfer RNA; FSGS = focal segmental glomerulosclerosis; TIN = tubulointerstitial nephritis.
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collage type IV are classically associated 
with Alport’s syndrome, and recent studies 
have shown that these mutations can be asso-
ciated with FSGS [18]. In our patient, whole 
exome sequencing did not reveal  COL4A3-5 
mutations.
While no cure currently exists for the 
management of MD-associated renal disease, 
organ transplantation remains a therapeutic 
option as in the case of our patient. Patients 
with MD are generally at risk for worsening 
of their disease by the catabolic stress associ-
ated with transplantation and associated risks 
of infection or medication-related toxicity. 
However, in a recent case series that ex-
amined the largest group of post-transplant 
patients (35 patients) with primary MDs to-
date who underwent either liver, kidney, or 
heart transplantation, the majority of patients 
did not have worsening of their MD within 
90 days of their transplantation [19]. The au-
thors also reported that post-transplant com-
plications, including organ rejection, were 
not a common occurrence. Our patient has 
had an uncomplicated post-transplant course 
following a living related kidney transplant 
from his father. As mitochondrial DNA dis-
eases are maternally transmitted, we would 
not expect the father to carry the same DNA 
change. If the diagnosis of maternally inher-
ited mitochondrial disease is known prior to 
transplant, maternal family donors should be 
avoided as they may also carry the mutation.
In conclusion, consideration of an under-
lying MD should be made in patients pre-
senting with the constellation of deafness, 
neurologic changes, diabetes, and protein-
uric renal failure. The case presented here 
adds to our current understanding of MD-
associated renal disease and is the first to 
provide genotype-phenotype evidence of a 
new FSGS-associated MD located at posi-
tion m.5538 G>A.
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